clinical trial · NCT06658535
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
Mild Respiratory Distressdodecafluoropentane (0.025 mL/kg)dodecafluoropentane (0.032 mL/kg)dodecafluoropentane (0.050 mL/kg)
brief summary
EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
started
Mar 13, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Jan 28, 2026
official title
Novel Oxygen Therapeutic NanO2 for Mild Respiratory Distress in Phase 1b
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol